Correlation Engine 2.0
Clear Search sequence regions


  • androgens (3)
  • cell (4)
  • exons (1)
  • humans (1)
  • impairs (1)
  • isoform (1)
  • male (1)
  • prostate (3)
  • regions (1)
  • relaxin (3)
  • RLN1 (11)
  • RLN2 (9)
  • rna (3)
  • sequence analysis (1)
  • sequence analysis, rna (1)
  • signal (1)
  • SMRT (1)
  • transcript (3)
  • Sizes of these terms reflect their relevance to your search.

    Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the relaxin field, and will encourage further studies of RLN1 and RLN2 in PCa and broader. Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

    Citation

    Gregor Tevz, Sean McGrath, Ryan Demeter, Vincent Magrini, Varinder Jeet, Anja Rockstroh, Stephen McPherson, John Lai, Nenad Bartonicek, Jiyuan An, Jyotsna Batra, Marcel E Dinger, Melanie L Lehman, Elizabeth D Williams, Colleen C Nelson. Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer. Molecular and cellular endocrinology. 2016 Jan 15;420:159-68

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 26499396

    View Full Text